Alcohol Withdrawal Syndrome

Definition

Alcohol withdrawal syndrome (AWS) is the clinical syndrome that occurs when a person with alcohol dependence or alcohol use disorder substantially reduces or stops alcohol consumption. ^[8]B3b In DSM-5-based clinical assessment, AWS is identified when at least 2 characteristic clinical signs or symptoms and/or related clinical manifestations occur after reduction or cessation of alcohol use. ^[4]B3b The diagnosis is therefore clinical and syndromic rather than based on a single laboratory value, alcohol concentration, or screening score. ^[4]B3b[8]B3b

AWS should be distinguished from alcohol use, alcohol intoxication, and a positive blood alcohol level. Hospitalized patients may be evaluated for alcohol exposure and withdrawal as separate clinical categories; a trauma cohort, for example, classified patients according to blood alcohol level or AWS diagnosis. ^[2]B3b The supplied studies do not establish a blood alcohol concentration threshold that rules AWS in or out, and they do not support using a positive or negative alcohol level alone as the definition of withdrawal. ^[2]B3b

Clinical classification

A practical classification is based on timing, severity, complications, and treatment response. AWS may be classified as:

1. Presenting AWS: withdrawal is clinically apparent at hospital admission. ^[8]B3b
2. Incident or developing AWS: withdrawal is not initially present but develops later during hospitalization. ^[8]B3b
3. Uncomplicated AWS: symptoms are present without documented seizure, delirium, or other major withdrawal complication. This term is useful clinically, but the supplied studies do not provide a single validated threshold separating uncomplicated from complicated disease. ^[1]B3b[8]B3b
4. Complicated or severe AWS: withdrawal is accompanied by major neurologic, autonomic, cardiovascular, or respiratory complications, including alcohol-withdrawal seizures, delirium tremens, severe agitation, arrhythmia, or need for intensive care. Delirium tremens was included with AWS as a discharge diagnosis in evaluation of a withdrawal protocol, supporting its use as a severe or complicated withdrawal term. ^[1]B3b Arrhythmias are clinically important complications of in-hospital AWS and are associated with increased mortality in a large national hospitalization analysis. ^[120]D
5. Resistant alcohol withdrawal (RAW): severe AWS that does not respond adequately to benzodiazepines despite escalating doses. RAW has been associated with increased mechanical ventilation, nosocomial pneumonia, and prolonged ICU stay. ^[9]B3b

These categories are descriptive and may overlap. For example, a patient can develop AWS after admission, progress to delirium or seizure, and subsequently meet criteria for resistant withdrawal if symptoms remain uncontrolled despite escalating benzodiazepine therapy. ^[8]B3b[9]B3b

Delirium tremens and withdrawal seizures

Delirium tremens (DT) is conventionally used for the delirious, severe end of the AWS spectrum; in the supplied evidence it appears as a diagnostic category paired with AWS rather than as a separately standardized case definition. ^[1]B3b Withdrawal seizures are likewise a major complication relevant to classification, although the supplied studies do not specify a universal seizure-based diagnostic threshold or timing criterion. ^[1]B3b[8]B3b Accordingly, the terms “complicated AWS,” “severe AWS,” and “DT” should not be treated as interchangeable in every clinical or research context. ^[1]B3b[9]B3b

Assessment terminology and nomenclature

“Alcohol withdrawal syndrome,” “AWS,” and “alcohol withdrawal” are used in the cited literature for the clinical condition associated with reduction or cessation of alcohol use. ^{[2]B3b[3]B2c[5]B2c[6]B3b[8]B3b} “Clinically recognized inpatient AWS” refers to withdrawal documented during a hospital encounter using clinical recognition and/or administrative diagnosis or procedure codes; prevalence estimates based on this terminology measure documented recognition, not necessarily all biologic withdrawal. ^[3]B2c

The Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar), and simplified derivatives such as the Highland Alcohol Withdrawal Protocol are assessment or treatment-guidance instruments, not standalone disease definitions. ^[1]B3b[6]B3b A hospital-wide CIWA-Ar protocol operationalizes symptom-based treatment, while the Highland protocol was evaluated as a simplified symptom-triggered tool. ^[1]B3b[6]B3b CIWA-based scoring can be problematic when symptoms have competing explanations: traumatic brain injury and AWS may produce overlapping signs, while their treatment strategies differ, and CNS depressants used for AWS may be undesirable in TBI. ^[119]C

No universally validated admission screening instrument was available in the hospitalized medical-surgical population examined by Pecoraro and colleagues; AUDIT-PC was studied as a predictor of subsequent AWS rather than as a diagnostic definition. ^[8]B3b Similarly, diagnosis codes used in observational studies identify study populations but do not create a universal clinical classification. ^{[2]B3b[3]B2c[6]B3b}

Classification limitations

The cited evidence demonstrates substantial variation in documented inpatient AWS across hospitals, regions, admitting services, and diagnostic contexts, emphasizing that nomenclature is influenced by recognition and documentation practices. ^[3]B2c Treatment strategy—fixed-dose, symptom-triggered, or front-loading benzodiazepines—describes management rather than AWS severity or diagnostic subtype. ^[5]B2c ICU-specific protocols and symptom-triggered approaches may affect outcomes, but protocol use should not be used to redefine AWS itself. ^[7]B3b

Core neuroadaptation

Alcohol withdrawal syndrome (AWS) reflects central nervous system hyperexcitation after a reduction or cessation of alcohol exposure ^[22]D5. Chronic alcohol exposure produces neuroadaptive changes in inhibitory γ-aminobutyric acid (GABA) and excitatory glutamate systems; when alcohol is removed, the resulting imbalance favors excessive excitatory neurotransmission and insufficient inhibition ^{[21]D5[22]D5[124]D}. Increased central N-methyl-D-aspartate (NMDA) glutamate transmission is specifically associated with AWS ^[17]A1b. This excitatory state provides the neurobiological basis for tremor, autonomic activation, agitation, hallucinations, seizures, and delirium tremens described across the clinical stages of withdrawal ^[22]D5.

The GABA–glutamate imbalance is also relevant to persistent symptoms after the acute withdrawal period ^[16]D5[124]D. Protracted or post-acute withdrawal is not uniformly defined, but is characterized by withdrawal-related symptoms continuing beyond the expected acute time frame ^[124]D. A systematic review found that post-acute alcohol withdrawal is dominated by negative affect beginning in early abstinence and potentially persisting for 4–6 months or longer ^[16]D5. Reported symptoms include anxiety, dysphoria, anhedonia, sleep disturbance, cognitive impairment, craving, and irritability ^[16]D5. These symptoms have been associated with recurrent alcohol consumption and may therefore contribute to relapse risk ^[16]D5.

Neurotransmitter and receptor mechanisms

The therapeutic activity of several withdrawal medications is consistent with this excitatory–inhibitory model. Benzodiazepines remain the standard pharmacological treatment and act through GABAergic mechanisms, while clinical management generally aims to restore inhibitory control and suppress central hyperexcitability ^[21]D5[22]D5. Propofol provides GABA_A receptor agonism at a binding site different from that of benzodiazepines and also reduces glutamatergic activity through NMDA receptor blockade ^[23]D5. These properties explain its consideration as an adjunct in refractory AWS, although the published literature reviewed consisted of clinical studies, case series, and case reports rather than definitive high-level comparative trials ^[23]D5.

Baclofen is a GABA_B receptor agonist and has been investigated as a mechanistically targeted alternative to benzodiazepines ^[15]A1b. A randomized comparative study enrolled 37 patients with AWS and assigned participants to baclofen or diazepam; baclofen was administered at 30 mg/day for 10 days, whereas diazepam was administered for 10 days with initial weight-based dosing followed by tapering ^[15]A1b. Multiple Cochrane reviews evaluated baclofen for AWS, including searches through 2010, 2012, 2015, 2017, and June 2019 ^{[10]A1a[11]A1a[12]A1a[13]A1a[14]A1a}. These reviews specifically assessed efficacy and safety, reflecting continuing uncertainty about the extent to which GABA_B modulation can substitute for standard GABAergic treatment ^{[10]A1a[11]A1a[12]A1a[13]A1a[14]A1a}.

Other agents have been used as pharmacological probes of the same circuitry. Dextromethorphan is a low-affinity, noncompetitive NMDA antagonist with proposed neuroprotective properties; however, a randomized, double-blind, placebo-controlled trial found no efficacy for managing moderate AWS ^[17]A1b. The study enrolled alcohol-dependent patients undergoing detoxification with revised Clinical Institute Withdrawal Assessment for Alcohol scores greater than 10 ^[17]A1b. This negative result indicates that NMDA antagonism alone, at the tested dextromethorphan regimen, may not adequately control clinical withdrawal ^[17]A1b.

Gamma-hydroxybutyric acid (GHB), which has activity relevant to inhibitory neurotransmission, was compared with clomethiazole in an open, randomized medical intensive-care study of 26 patients with severe AWS and concomitant medical illness ^[18]A1b. Tremor, sweating, nausea, and restlessness were among the principal symptoms scored in that study ^[18]A1b. Levetiracetam combined with tiapride was evaluated in an open outpatient case series involving 9 alcohol-dependent patients treated for a maximum of 7 days, with daily withdrawal severity measured using the Alcohol Withdrawal Syndrome Scale ^[117]C4. All patients completed treatment successfully, but the uncontrolled design limits mechanistic or efficacy conclusions ^[117]C4.

Autonomic and cardiovascular hyperactivity

AWS-related changes in the peripheral and central β-adrenergic systems alter cardiovascular responses during withdrawal ^[19]C4. In a study of 20 alcohol-dependent subjects, propranolol responses during withdrawal differed from responses during remission, with changes in negative chronotropy and hypotension; baseline haemodynamics were the strongest modifier of response, and daily alcohol consumption also contributed ^[19]C4. These findings support autonomic dysregulation as a component of withdrawal pathophysiology but do not establish β-adrenergic blockade as treatment for the underlying excitatory state ^[19]C4.

Dexmedetomidine has been studied as an adjunct to benzodiazepine therapy in intensive-care patients with AWS delirium because benzodiazepines may inadequately control delirium when inhibitory and excitatory neurotransmission remain imbalanced ^[109]A1a. Its proposed clinical role is therefore adjunctive control of severe autonomic and delirium manifestations rather than correction of the primary neuroadaptation ^[109]A1a.

Nutritional and emerging mechanisms

Pyridoxal-5′-phosphate, the active form of vitamin B6, is a cofactor for glutamic acid decarboxylase, the rate-limiting enzyme converting glutamate to GABA ^[123]D. A 2026 hypothesis paper proposes that deficiency may worsen the glutamatergic/GABAergic imbalance in AWS and that repletion could improve withdrawal outcomes and promote abstinence; this remains hypothesis-level evidence ^[123]D.

Sigma-1 receptor mechanisms are an emerging research area. Preclinical evidence indicates that sigma-1 receptor antagonists may reduce alcohol intake, motivation to drink, and alcohol-seeking behaviour, while potentially improving alcohol-related cognitive and motor abnormalities and relapse-like behaviour ^[20]D5. These findings are preliminary and do not yet establish a clinical neurobiological treatment for AWS ^[20]D5.

Epidemiology

Alcohol withdrawal syndrome (AWS) is a clinically important reason for emergency and inpatient care, but its measured frequency varies according to the population studied and the method used to identify cases. A large U.S. electronic-health-record study evaluated emergency-department presentations coded for AWS from 2016 through 2023, using the Epic Cosmos database; the study was designed to quantify the proportion of emergency visits involving AWS, admission rates, length of stay, and medications administered. ^[127] A separate population-based cohort used Kaiser Permanente Washington primary-care records and insurance claims from July 2018 through June 2022 to estimate the incidence and proportional incidence of hospitalizations involving AWS among adults receiving primary care and standardized alcohol screening. ^[128]

Hospital-based estimates are particularly relevant because AWS may be present at admission or develop during hospitalization. The Kaiser Permanente study specifically examined incidence across patient characteristics, underscoring that the observed burden is not uniform across demographic or clinical subgroups. ^[128] AWS was also investigated in specialized or high-risk inpatient populations, including patients hospitalized with alcohol-associated hepatitis (AH), trauma patients, critically ill surgical-trauma patients, psychiatric inpatients, and patients admitted to alcohol-related disease units. ^{[30]B2b[31]B2b[131][135][125]}

In patients hospitalized with AH, the prevalence, predictors, management, and clinical impact of AWS were evaluated retrospectively across five medical centers in Spain and the United States between January 2016 and January 2021. ^[30]B2b This population is clinically important because AWS may complicate admission for severe alcohol-related liver disease; however, the supplied study abstract does not provide the numerical prevalence estimate. ^[30]B2b In Japan, a retrospective study of 88 patients hospitalized with alcoholic hepatitis examined delirium tremens (DT), associated risk factors, and outcomes, reflecting the potential for AWS-related complications to be missed when specialized addiction services are unavailable. ^[40]C4

Sex and age distributions are increasingly being examined rather than assuming that AWS is predominantly a disorder of men. A tertiary alcohol-related disease-unit cohort included 907 patients with alcohol use disorder (AUD), of whom 238 (26.2%) were women, admitted between 2004 and 2022. ^[125] The authors noted that AUD has historically been more prevalent among men and reported sex-specific clinical and psychiatric phenotypes, including AWS manifestations. ^[125] Another hospital cohort included 16,190 hospitalizations representing 10,092 patients, with women comprising 30.2% of the study population; participants were categorized into four age groups: 21–39, 40–64, 65–74, and 75 years or older. ^[36]B2b These data support evaluating AWS risk and presentation across sex and age rather than restricting case recognition to middle-aged men. ^[36]B2b[125]

Etiology and ascertainment

The evidence base supplied here is predominantly observational and focuses on patients already identified as having AWS. Consequently, it describes clinical burden and associated conditions more reliably than population-level causation. ^{[30]B2b[31]B2b[36]B2b[40]C4[125][127][128]} Case ascertainment differed substantially: the AH study used clinical criteria plus sedative use to control AWS symptoms, ^[30]B2b the emergency-department study used relevant ICD-10 codes, ^[127] and hospital protocol studies identified patients through electronic order sets or structured withdrawal assessments such as CIWA-Ar or MINDS-based systems. ^{[6]B3b[130][135]} These differences can change apparent prevalence and may preferentially identify patients with clinically recognized or treated withdrawal. ^{[6]B3b[30]B2b[127][130][135]}

The included literature concerns AWS occurring in the context of AUD or heavy alcohol exposure. In the trauma-center study, “heavy drinking” was operationalized as daily drinking or more than 7 drinks per week, and investigators assessed its relationship with AWS among 1,011 adults admitted to a level I trauma center who had blood alcohol concentration testing. ^[31]B2b The study excluded patients with severe traumatic brain injury defined by a Glasgow Coma Scale score of 8 or less, helping reduce diagnostic overlap between neurologic injury and withdrawal manifestations. ^[31]B2b

Risk factors and high-risk clinical settings

Important risk-assessment settings include trauma, AH, alcoholic hepatitis with possible acute-on-chronic liver failure, psychiatric hospitalization, and critical illness. ^{[30]B2b[31]B2b[40]C4[131][135]} The trauma study was specifically designed to identify combinations of admission conditions that could estimate the probability of AWS, because the proportion of trauma patients developing AWS was considered low and individual risk conditions had not been precisely delineated. ^[31]B2b The Japanese alcoholic-hepatitis study examined DT and other risk factors in a setting where patients may lose contact with care after DT, potentially allowing critical events to be missed. ^[40]C4

Prior AWS-management cohorts also demonstrate that severity is clinically heterogeneous. Studies enrolled patients with moderate-to-severe inpatient AWS, critically ill AWS, or protocol-defined withdrawal, and evaluated outcomes including seizures, DT, severe agitation, pneumonia, intensive-care use, and treatment resistance. ^{[32]A1a[129][131][132]C} A Chinese retrospective study of hospitalized patients with acute AWS examined whether a low sarcopenia index predicted pneumonia, illustrating that frailty and nutritional or muscle-related characteristics may influence complications after AWS has developed; the supplied abstract does not establish that sarcopenia causes AWS itself. ^[132]C Similarly, studies of phenobarbital-resistant AWS evaluated resistance after treatment initiation and therefore address predictors of difficult-to-control withdrawal rather than predictors of developing AWS in the general population. ^[129]

Overall, the strongest recurring epidemiologic signal is concentration of AWS in patients with AUD or heavy alcohol exposure who present to emergency, inpatient, trauma, liver, psychiatric, or intensive-care services. ^{[30]B2b[31]B2b[125][127][128][131][135]} Available studies support systematic screening across sex and age groups and careful differentiation of AWS from trauma, hepatic encephalopathy, infection, medication effects, and other causes of agitation or altered mental status; however, the references supplied do not provide a single validated universal risk score or a definitive causal hierarchy of individual risk factors. ^{[31]B2b[36]B2b[40]C4[128]}

Overview

Alcohol withdrawal syndrome (AWS) is a potentially life-threatening clinical condition that may occur after reduction or cessation of alcohol in a person with chronic, heavy alcohol consumption or alcohol use disorder (AUD). Its severity ranges from mild autonomic and subjective symptoms to seizures, delirium tremens (DT), respiratory complications, and death. ^{[44]A1c[46]A1a} Clinical assessment should therefore consider both current symptoms and the patient’s risk of progression to complicated withdrawal. ^{[50]B2a[93]B2c}

AWS has been described as having acute, early, and protracted phases. Protracted alcohol withdrawal (PAW) may persist for weeks, months, or, in some reports, years after cessation, although the systematic-review evidence most consistently concerns craving and sleep disturbance. ^[47]A1a

Acute and early manifestations

The clinical picture commonly includes anxiety, subjective distress, sleep disturbance, craving, and symptoms of autonomic or neuropsychiatric activation. ^{[47]A1a[61]A1b} Anxiety and depressive symptoms may be prominent during the withdrawal course and have been evaluated serially with standardized anxiety and depression scales in clinical studies. ^[61]A1b Craving generally declines over time after cessation, with pooled obsessive-compulsive drinking scale scores reported to decrease from 24.2 at baseline to 18.8 at 1 week, 10.3 at 1 month, and 9.7 at 3 months. ^[47]A1a

Symptoms may evolve from uncomplicated withdrawal to moderate or severe AWS. In a randomized inpatient trial, participants were considered to have clinically significant withdrawal when their baseline Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) score was greater than 8. ^[52]A1b In contrast, uncomplicated outpatient AWS has also been studied using CIWA-Ar-based enrollment criteria, demonstrating that the syndrome can be clinically apparent without seizures or delirium. ^[49]A1b

Complicated withdrawal

The principal severe complications are alcohol-related seizures and DT. Severe AWS has been operationalized as a composite of DT, withdrawal seizure, or requirement for high benzodiazepine doses. ^[137] Alcohol-related seizures are an important consequence of AWS and may occur in patients with otherwise variable withdrawal severity; their relationship with DT and overall AWS severity has been specifically examined in a large retrospective cohort and follow-up study. ^[139]C A history of complicated withdrawal, including prior withdrawal seizures or DT, is clinically important when estimating future risk. ^[50]B2a

Risk prediction tools are intended to identify patients likely to develop complicated withdrawal rather than merely quantify symptoms after AWS has begun. The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) was developed because commonly used symptom scales, including CIWA, do not identify in advance which medically ill patients are at risk for complicated AWS. ^[50]B2a The Alcohol Withdrawal Triage Tool (AWTT) was developed to predict severe AWS and hospital-admission need using objective information available during an emergency-department evaluation; its severe-outcome definition included DT, seizure, or high benzodiazepine exposure. ^[137] Machine-learning models have likewise been investigated for predicting moderate-to-severe withdrawal, DT, and withdrawal seizures from admission clinical, laboratory, and sociodemographic variables, although these approaches should not replace clinical judgment. ^[93]B2c

Delirium, cognition, and assessment limitations

DT represents a severe neuropsychiatric manifestation of AWS and should be considered when agitation or altered mental status is accompanied by suspected withdrawal. ^[137][139]C CIWA-Ar scores may be difficult to interpret when symptoms arise from another condition. Traumatic brain injury and AWS can produce overlapping findings, while their treatments differ; use of a CIWA-guided protocol in patients with TBI may consequently lead to administration of central nervous system depressants that are undesirable in TBI. ^[119]C

Alcohol-related illness may also complicate interpretation of mental-status, gastrointestinal, neurologic, and dermatologic findings. Alcoholic pellagra may present with skin lesions, diarrhea, or mental disorders, and the classical triad may be absent, creating potential diagnostic confusion with other alcohol-related diseases. ^[51]C4 Alcohol-associated chronic pain and withdrawal-related changes in pain experience may coexist, and the relationship between AUD and chronic pain can be bidirectional. ^[29]D5

Important alternative diagnoses and comorbidity

Seizures, confusion, fever, headache, or systemic illness should not automatically be attributed to AWS. In a population-based study of alcoholic patients with community-acquired bacterial meningitis, 18% presented with seizures and 23% had co-existing pneumonia; Streptococcus pneumoniae, Listeria monocytogenes, and Neisseria meningitidis were the leading reported organisms. ^[48]B2b Hospitalized patients with acute AWS may also develop pneumonia, and a low sarcopenia index was investigated as a prognostic factor for pneumonia risk. ^[132]C

Clinical evaluation should therefore document the timing and pattern of alcohol reduction or cessation, prior withdrawal complications, current autonomic and neuropsychiatric symptoms, seizure activity, mental status, nutritional and medical comorbidity, and possible mimics. ^{[44]A1c[50]B2a[119]C[137]} Persistent craving, sleep disturbance, anhedonia, anxiety, or depressive symptoms after resolution of acute autonomic findings may represent PAW rather than ongoing severe acute withdrawal. ^{[47]A1a[61]A1b}

Establishing the diagnosis of alcohol withdrawal syndrome (AWS) requires a clinical synthesis of recent cessation or reduction in heavy alcohol use and the emergence of characteristic autonomic and neuropsychiatric symptoms. Because AWS often complicates acute medical admissions, the diagnostic process must simultaneously quantify withdrawal severity and exclude life-threatening organic mimics ^{[27]A1a[30]B2b}.

Clinical Criteria and History

Diagnosis is primarily clinical, based on the presence of at least two symptoms following the reduction of prolonged alcohol intake: autonomic hyperactivity (e.g., sweating, tachycardia), increased hand tremor, insomnia, nausea or vomiting, transient hallucinations, psychomotor agitation, anxiety, or generalized tonic-clonic seizures ^[56]A1c.

Key historical and physical findings that increase the likelihood of progressing to severe alcohol withdrawal syndrome (SAWS) include:

• History of delirium tremens (LR 2.9) ^[27]A1a.
• Baseline systolic blood pressure ≥140 mm Hg (LR 1.7) ^[27]A1a.
• Previous history of AWS (OR 2.09) ^[30]B2b.
• Lower platelet levels (OR 1.61) ^[30]B2b.

Validated Rating Scales

Standardized tools are essential for objective monitoring and to guide symptom-triggered therapy, which has been shown to reduce treatment duration by a mean of 60.4 hours compared to fixed-dose regimens ^[54]A1a.

• CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol - Revised): The gold-standard tool for evaluating AWS severity ^[55]A1a. It assesses 10 signs/symptoms including nausea, tremor, paroxysmal sweats, anxiety, agitation, tactile/auditory/visual disturbances, headache, and orientation ^[60]A1b.
• PAWSS (Prediction of Alcohol Withdrawal Severity Scale): A highly effective tool for identifying patients at high risk for SAWS. A score of 4 or more findings has a likelihood ratio (LR) of 174 and a specificity of 0.93, while a score of 3 or fewer has an LR of 0.07 and a sensitivity of 0.99 ^[27]A1a.
• Wetterling Scale: Used to categorize withdrawal as mild (<6), moderate (6-9), or severe (>9). Higher maximum scores on this scale are independently associated with increased length of stay and in-hospital mortality ^[58]B3b.

Organic Rule-Out and Laboratory Workup

AWS is a diagnosis of exclusion in the setting of altered mental status or seizures. Clinicians must rule out co-occurring conditions that can mimic or exacerbate withdrawal symptoms.

Diagnostic Algorithm

1. Screen for Risk: Utilize the PAWSS tool upon admission for any patient with a history of heavy alcohol use ^[27]A1a.
2. Confirm Cessation: Document the timing of the last drink; symptoms typically emerge within 6-24 hours ^[56]A1c.
3. Baseline Assessment: Obtain vital signs and perform a physical exam focusing on tremors and autonomic hyperactivity ^[27]A1a.
4. Rule Out Mimics: Order CBC (assess for thrombocytopenia), CMP (assess for electrolyte derangements and liver function), and consider CT head or lumbar puncture if focal deficits or fever are present ^{[30]B2b[48]B2b[53]A1c}.
5. Severity Stratification: Initiate serial CIWA-Ar scoring (e.g., every 1-4 hours depending on severity) to guide pharmacological intervention ^{[54]A1a[55]A1a}.

Pearl: A PAWSS score of 4 or more is the most robust predictor of severe withdrawal (LR 174), and its use should trigger aggressive prophylaxis or ICU-level monitoring ^[27]A1a.

Clinical severity is dynamic

Alcohol withdrawal syndrome (AWS) should be treated as a potentially progressive clinical condition rather than a single baseline score. The 2020 American Society of Addiction Medicine guideline addresses adults hospitalized with AWS of any severity and provides a framework for monitoring, prevention of complications, escalation of care, and treatment selection. ^[65]A1c Severity assessment should therefore be repeated after admission and after pharmacologic intervention, with attention to autonomic activation, agitation, perceptual disturbance, confusion, seizures, respiratory status, and the need for increasingly intensive monitoring. ^[65]A1c

The Clinical Institute Withdrawal Assessment for Alcohol—Revised (CIWA-Ar) is widely used to quantify symptoms and follow their evolution. A systematic review and meta-analysis specifically evaluated whether aggregate CIWA-Ar scores track the course of AWS and compared benzodiazepine and non-benzodiazepine treatment approaches. ^[55]A1a However, CIWA-Ar is a symptom scale and should not be interpreted in isolation when patients cannot communicate reliably, are delirious, are intubated, have severe medical or psychiatric comorbidity, or have symptoms that may reflect another diagnosis. This limitation is clinically important because a multicenter observational study evaluated both CIWA-Ar scores and medication doses as possible markers of patients requiring high-intensity care, rather than assuming that the score alone defines escalation needs. ^[144]

Risk stratification before severe withdrawal develops

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) is an important pre- or early-withdrawal risk-stratification instrument. In a randomized inpatient trial, patients were defined as being at risk for complicated withdrawal when PAWSS ≥4; 88 hospitalized adults meeting this criterion were randomized within 16 hours of admission to fixed-dose gabapentin or CIWA-Ar-directed benzodiazepines. ^[70]B2b A hospital screening protocol also used universal PAWSS screening, followed by the Glasgow Modified Alcohol Withdrawal Scale (GMAWS) for patients identified as at risk. ^[143] These studies support separating prediction of complicated withdrawal from measurement of current symptom intensity: PAWSS identifies risk, whereas CIWA-Ar or GMAWS measures clinically expressed symptoms. ^[70]B2b[143]

Trauma populations may require additional risk assessment. A retrospective Level I trauma-center study examined associations between AWS and candidate risk conditions, including heavy drinking defined as daily alcohol consumption or more than 7 drinks per week; patients with a Glasgow Coma Scale score of ≤8 were excluded. ^[31]B2b A separate case-control study of 3,896 adult trauma patients classified participants by blood alcohol concentration and AWS status to examine the relationship between alcohol exposure, withdrawal, and hospital outcomes. ^[2]B3b These studies underscore that trauma presentation, intoxication, and withdrawal may coexist, and that neurologic or behavioral findings should not automatically be attributed to AWS. ^{[2]B3b[31]B2b}

High-risk clinical contexts

Comorbidity can alter both the apparent severity and the consequences of AWS. In a multinational retrospective cohort of patients hospitalized with alcohol-associated hepatitis, investigators examined AWS prevalence, predictors, management, and mortality while adjusting for demographic factors and disease severity. ^[30]B2b In a separate retrospective comparison, patients with liver disease who underwent CIWA-Ar-based management had a higher prevalence of alcohol use disorder and a longer median hospital stay than patients without liver disease; reported median lengths of stay were 93 hours versus 69 hours, respectively. ^[142] These findings support early assessment of hepatic disease and other medical complications when determining monitoring intensity and disposition. ^[30]B2b[142]

Pregnancy and the early postpartum period represent another high-risk context. In a Mayo Clinic retrospective series of eight pregnant patients treated under a CIWA-Ar protocol, withdrawal was clinically substantial, with a median peak CIWA-Ar score of 17 and an interquartile range of 14; maternal and fetal outcomes were also examined. ^[140]C Because the evidence is limited to a small retrospective cohort, these observations should not be used as a universal severity threshold, but they support specialist obstetric and medical involvement when AWS occurs during pregnancy or early postpartum. ^[140]C

Course monitoring and treatment implications

Evidence on the course of AWS is closely linked to the intervention used. A systematic review-based meta-analysis evaluated whether CIWA-Ar trajectories correspond to withdrawal progression and treatment response. ^[55]A1a Evidence syntheses of phenobarbital and other non-benzodiazepine therapies found that phenobarbital remains a potential alternative to benzodiazepines, but appropriate dosing and the comparative evidence base remain uncertain. ^[66]A1a Reviews of non-benzodiazepine and non-barbiturate medications likewise identified randomized evidence for alternatives in moderate-to-severe AWS but emphasized limitations in the available evidence. ^[68]B2a A meta-analysis of randomized trials reported a benefit favoring gabapentin over chlordiazepoxide and lorazepam, with an effect size of d = 0.563, although applicability depends on patient selection and setting. ^[71]A1a

In hospitalized patients at risk for complicated withdrawal, fixed-dose gabapentin was directly compared with CIWA-Ar-directed benzodiazepines in an open-label randomized trial. ^[70]B2b Anticonvulsant evidence for moderate-to-severe inpatient AWS has also been systematically reviewed, including outcomes such as symptom improvement, seizures, delirium tremens, and adverse events. ^[32]A1a Magnesium should not be assumed to modify severity solely because hypomagnesemia is associated with AWS; a multicenter double-blind randomized trial enrolled inpatients with baseline CIWA-Ar >8 to test oral magnesium as adjunctive therapy. ^[52]A1b

Severity should therefore be reassessed using symptoms, trajectory, complications, comorbidity, and treatment requirements—not a single numeric score. Patients with worsening scores, seizures, delirium, escalating sedative requirements, impaired airway protection, or other organ dysfunction warrant a higher-acuity evaluation consistent with the ASAM guideline framework. ^[65]A1c[144]

Immediate assessment and disposition

Alcohol withdrawal syndrome (AWS) is a medical emergency that may produce severe complications, including delirium tremens (DT), and requires early assessment of symptom severity, complication risk, comorbid illness, medication or substance exposure, and the need for monitored care.^{[44]A1c[74]A1a} The Society for Academic Emergency Medicine GRACE-4 guideline used the GRADE framework to address six priority questions concerning adult emergency-department (ED) patients with AWS, alcohol use disorder (AUD), and cannabinoid hyperemesis syndrome; recommendations should therefore be interpreted according to the patient’s clinical severity and available monitoring resources.^[44]A1c Recent United States data and multicenter hospital studies describe AWS as a substantial and variable component of acute-care practice, with variation in admission patterns, medications, order sets, and guideline concordance.^{[111]B3b[127][149]}

Patients with suspected severe AWS, seizures, hallucinations, marked autonomic instability, confusion, or evolving delirium require urgent clinician assessment and a setting capable of frequent reassessment and management of respiratory or neurologic deterioration.^{[44]A1c[73]A1a[74]A1a} DT is a serious AWS complication, and loss of clinical contact after DT may contribute to missed critical events; continued observation and follow-up after apparent delirium resolution are therefore important.^[40]C4 Biomarker abnormalities involving biochemical, hematologic, inflammatory, and gut-permeability measures have been described in patients with DT, but these findings were obtained after the acute episode and do not establish a validated bedside diagnostic test.^[148]

Pharmacologic treatment

Benzodiazepines remain the established first-line pharmacotherapy for AWS in the direct-evidence reviews, although treatment protocols and dosing approaches vary.^{[73]A1a[74]A1a[111]B3b} Symptom-guided treatment should be used only when the patient can participate reliably in assessment; confusion, delirium, severe illness, or inability to communicate may limit the validity of symptom scores and should prompt clinical rather than score-only decision-making.^[44]A1c

Phenobarbital (PB) is a potential alternative or adjunct when benzodiazepines are insufficient or unavailable, but the certainty of evidence, optimal dosing, and comparative safety remain incompletely defined.^{[66]A1a[73]A1a[74]A1a} The 2024 systematic review and meta-analysis compared PB with benzodiazepines in ED AWS and found that the evidence base was mixed; its inclusion criteria comprised randomized and cohort studies, with 8 of 59 screened abstracts (13.6%) meeting criteria.^[73]A1a A separate direct-evidence review specifically evaluated AWS complications, monitored-setting admission, symptom control, adverse effects, and adjunctive medication use, but concluded that the available evidence remains limited.^[74]A1a A 2025 single-center retrospective cohort of 1,178 adults compared intravenous PB monotherapy, intravenous benzodiazepines, and combination therapy for admission and ED operational outcomes; because this was observational and single-center, it should not be interpreted as definitive comparative efficacy evidence.^[113]B3b

Gabapentin should not routinely replace benzodiazepines for severe or complicated AWS on the basis of current evidence. A systematic review and meta-analysis identified 8 retrospective studies involving 2,030 patients, with no randomized trials, and evaluated symptom resolution, benzodiazepine exposure, complications, and length of stay.^[75]A1a These data support uncertainty regarding gabapentin as a benzodiazepine-sparing or replacement strategy, particularly in high-risk withdrawal.^[75]A1a

Baclofen and vigabatrin remain investigational or adjunctive options rather than established first-line treatments. In a single-blind randomized trial of 63 inpatients receiving benzodiazepine-assisted detoxification, baclofen at 30 or 60 mg/day for 7 days was compared with placebo, with diazepam administered as needed according to the Clinical Institute Withdrawal Assessment for Alcohol–revised; the study was designed to assess additional diazepam requirements, but available evidence remains insufficient to support baclofen-assisted withdrawal as routine care.^[77]A1b A double-blind randomized trial assigned 120 residential-withdrawal patients to vigabatrin 2 g/day for 4 days or placebo and assessed the need for, and total dose of, diazepam; this benzodiazepine-sparing approach requires interpretation within the residential setting and does not establish ED standard therapy.^[78]A1b Oral ethanol prescribing has been reported retrospectively in selected UK acute-care patients at high risk, including those with harmful consumption typically of ≥30 UK units/day, prior severe withdrawal, seizures, or DT; this lower-level evidence should not displace guideline-based pharmacotherapy.^[147]C

Psychiatric and post-acute emergencies

Acute AWS may coexist with anxiety, dysphoria, irritability, craving, sleep disturbance, cognitive impairment, anhedonia, or other negative-affect symptoms that can persist beyond detoxification.^{[16]D5[47]A1a} Post-acute withdrawal symptoms may last 4–6 months or longer and are associated with recurrent alcohol consumption; pooled craving scores in the systematic review declined from 24.2 at baseline to 18.8 at 1 week, 10.3 at 1 month, and 9.7 at 3 months.^{[16]D5[47]A1a} Psychiatric assessment should therefore continue after autonomic symptoms improve and should address persistent affective symptoms, cognition, sleep, craving, relapse risk, and immediate safety concerns.^{[16]D5[47]A1a}

Adjuncts, monitoring, and systems of care

Percutaneous auricular vagus-nerve stimulation has only pilot-level evidence: an open-label, single-arm study enrolled 30 patients with AUD undergoing AWS and assessed autonomic responses; it should not be considered an established acute treatment.^[76]B2b Economic evidence remains sparse: a 2025 systematic review screened 6,347 records, included 8 studies, and emphasized the need to evaluate both clinical effectiveness and resource use.^[72]B2a Hospital order-set research has examined laboratory assessment, severe-AWS risk assessment, symptom treatment, and complication management, highlighting the importance of protocol quality, although the study was descriptive rather than an intervention trial.^[149] Disposition should integrate clinical trajectory, comorbidity, social support, reliable follow-up, and the capacity to monitor for recurrent withdrawal or psychiatric deterioration.^{[44]A1c[40]C4}

Scope and treatment goals

Alcohol withdrawal syndrome (AWS) management is an acute stabilization intervention and should be followed by definitive treatment of alcohol use disorder (AUD), including relapse-prevention medication, psychosocial treatment, and continuing addiction care. The references supplied for this section primarily evaluate acute withdrawal treatment; they provide limited direct evidence for psychotherapy, long-term pharmacotherapy, or somatic/neuromodulation treatment after detoxification. ^{[57]A1a[81]A1b[83]D5}

Psychotherapy remains an important component of definitive AUD care, but none of the supplied studies directly compares cognitive-behavioral therapy, motivational interviewing, relapse-prevention therapy, mutual-help participation, contingency management, or other structured psychosocial interventions after AWS. Accordingly, no psychotherapy modality can be ranked from this reference set. ^{[37]B2b[83]D5}

Pharmacotherapy during withdrawal

Benzodiazepines remain the principal pharmacologic treatment evaluated in these studies. A prospective randomized trial comparing benzodiazepine loading with symptom-triggered treatment found reductions in CIWA-Ar scores with both strategies; the mean rate of score change was −1.5 ± 1.3 in the symptom-triggered group and −2.3 ± 2.5 in the loading group. ^[82]A1b A randomized trial of intravenous phenobarbital added to a standardized lorazepam protocol assessed ICU admission, but the supplied abstract does not report the complete primary-outcome result. ^[85]A1b

A 2023 network meta-analysis of 41 studies involving 4,187 participants found no significant difference in CIWA-Ar reduction between benzodiazepines and other medications or medication combinations. Anticonvulsant plus benzodiazepine therapy was associated with a pooled ICU-stay reduction of 1.71 days versus benzodiazepines alone (95% CI, −2.82 to −0.59), although this finding concerns acute care rather than long-term AUD treatment. ^[57]A1a

Phenobarbital is a possible alternative or adjunct in severe or benzodiazepine-resistant AWS, but the evidence is heterogeneous and requires monitored use because of cumulative sedation and respiratory-depression risk. A systematic review of seven clinical studies evaluated barbiturates against benzodiazepines for delirium duration, seizures, ICU and hospital length of stay, medication exposure, and cardiopulmonary complications. ^[45]A1a A 2025 retrospective emergency-department cohort of 1,178 adults compared intravenous phenobarbital monotherapy, benzodiazepines, and combination treatment for admission, ED length of stay, and 72-hour return visits; observational design limits causal interpretation. ^[113]B3b Other retrospective studies examined phenobarbital with benzodiazepines, including comparisons with benzodiazepine monotherapy and with dexmedetomidine, but their nonrandomized designs and potential confounding prevent establishing phenobarbital as definitive long-term therapy. ^{[114]B3b[126]}

Dexmedetomidine may reduce autonomic hyperactivity and benzodiazepine exposure in selected ICU patients, but it does not constitute definitive AUD treatment. In a matched retrospective cohort, early dexmedetomidine addition was evaluated for 12- and 24-hour benzodiazepine requirements, symptom control, ICU and hospital stay, mechanical ventilation, bradycardia, and hypotension. ^[87]B3b A separate retrospective comparison reported outcomes for dexmedetomidine/lorazepam versus phenobarbital/lorazepam, including hospital and ICU length of stay and mechanical ventilation. ^[114]B3b

Several non-benzodiazepine agents have limited or condition-specific evidence. Baclofen was compared with chlordiazepoxide in a randomized open-label study of 60 participants with uncomplicated AWS, using CIWA-Ar scores and rescue lorazepam as clinical measures. ^[88]B2b A systematic review and meta-analysis reported significant AWS symptom reduction with tiapride plus carbamazepine, but the combination should not be interpreted as established maintenance treatment for AUD. ^[80]A1a Oral magnesium lactate supplementation, providing 426.6 mg/day for up to 15 days, was tested as adjunctive treatment in inpatients with baseline CIWA-Ar scores >8 in a multicenter randomized trial. ^[52]A1b Intranasal oxytocin was studied in a double-blind randomized trial of 40 alcohol-dependent inpatients receiving symptom-triggered oxazepam over three days; the supplied abstract describes the design but does not provide complete outcome data. ^[81]A1b

Dextromethorphan did not demonstrate efficacy in a preliminary randomized, double-blind, placebo-controlled study of moderate AWS, defined by CIWA-Ar >10. ^[17]A1b Sodium oxybate has post-marketing and clinical safety experience in AUD, including data from randomized studies involving 520 participants and earlier studies involving 2,547 participants, but this evidence addresses safety and approved use in selected jurisdictions rather than a general recommendation for post-withdrawal maintenance. ^[83]D5 Ethanol prescribing has been reported retrospectively in high-risk patients, including those with harmful consumption typically ≥30 UK units/day, previous severe withdrawal, seizures, or delirium tremens; it is not established as routine definitive therapy. ^[147]C Ethanol plus lorazepam was also evaluated against lorazepam alone in a small randomized pilot study of 57 patients with myocardial infarction. ^[84]A1b

Definitive AUD treatment and care transition

Hospitalization for AWS is an opportunity to initiate or arrange evidence-based medication for AUD and addiction follow-up, but the supplied evidence does not compare specific maintenance agents or demonstrate long-term outcomes. A 2026 retrospective study specifically examined demographic and language differences in discharge prescriptions for AUD medication, highlighting discharge prescribing as a measurable component of care quality rather than proving efficacy of any particular agent. ^[37]B2b

Somatic and neuromodulation therapies

No supplied reference directly evaluates electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct-current stimulation, vagus-nerve stimulation, deep-brain stimulation, or another somatic/neuromodulation intervention for definitive AWS or AUD treatment. These therapies therefore cannot be recommended or ranked on the evidence provided. ^{[17]A1b[57]A1a[83]D5}

Safety and escalation principles

High-dose sedative treatment for severe AWS may be delivered without routine immediate intubation in experienced ICUs, but observational data have evaluated pneumonia and endotracheal-intubation risks rather than establishing a universal strategy. ^[138]C Propofol has been examined as an adjunct to escalating benzodiazepines in benzodiazepine-resistant AWS, defined in one healthcare-system study as ≥40 mg diazepam within 1 hour; the evidence was retrospective and specifically concerned acute refractory withdrawal. ^[150]C These findings reinforce that adjunctive sedatives, barbiturates, alpha-2 agonists, and other agents require monitored individualized care and should not replace transition to longitudinal AUD treatment. ^{[45]A1a[87]B3b[114]B3b[150]C}

Transitioning from acute pharmacological stabilization to a maintenance or adjunctive regimen requires a structured surveillance engine to mitigate iatrogenic harm. While benzodiazepines remain the cornerstone of treatment, the introduction of antipsychotics, antibiotics , or vasoactive agents in the context of alcohol withdrawal syndrome (AWS) necessitates rigorous monitoring of cardiac and metabolic parameters to prevent life-threatening arrhythmias ^[92]C4.

Cardiac and Electrophysiological Surveillance

Patients undergoing treatment for AWS frequently possess multiple risk factors for proarrhythmic responses, including electrolyte disturbances and autonomic instability. The risk of torsade de pointes is significantly elevated when QT-prolonging agents are administered to patients with underlying metabolic derangements ^[92]C4.

• ECG Monitoring: Baseline and serial 12-lead ECGs are required when using adjunctive antipsychotics or when the patient has comorbid conditions (e.g., HIV, chronic liver disease).
• QT Interval Assessment: A prolonged QT interval can be exacerbated by the concomitant use of antibiotics (e.g., piperacillin / tazobactam , metronidazole ) and vasoactive support such as dopamine ^[92]C4.
• Electrolyte Optimization: Aggressive correction of hypokalaemia and hypomagnesemia is mandatory, as these deficiencies lower the threshold for ventricular arrhythmias during the withdrawal state ^[92]C4.

Autonomic and Hemodynamic Monitoring

Pharmacological management must be balanced against the patient's fluctuating autonomic tone. Surveillance should focus on the following parameters:

• Heart Rate: Monitoring for sinus bradycardia or compensatory tachycardia, which may signal either over-sedation or worsening withdrawal ^[92]C4.
• Blood Pressure: Assessment for hypotension, particularly when using agents that modulate alpha-adrenergic or dopaminergic pathways ^[92]C4.
• Rhythm Analysis: In high-risk patients, 24-hour Holter monitoring or continuous telemetry may be necessary to detect self-terminating episodes of torsade de pointes or frequent ventricular premature complexes ^[92]C4.

Metabolic and Hematologic Surveillance

For patients transitioned to long-term psychiatric stabilizers or those requiring clozapine or anticonvulsants, a protocolized monitoring schedule is essential to track metabolic and hematologic health. This includes regular metabolic panels to screen for drug-induced dyslipidemia or glucose intolerance, and complete blood counts for patients on agents with known marrow toxicity.

ECG Findings in AWS Management

Pearl: Hospitalized patients with AWS often have multiple silent risk factors for proarrhythmic responses; always review the medication profile for QT-prolonging drugs and correct even mild hypokalaemia immediately to prevent torsade de pointes ^[92]C4.

Purpose and safety frame

Severe alcohol withdrawal syndrome (SAWS) is clinically important because it may include delirium tremens, withdrawal seizure, or clinically diagnosed severe withdrawal, and untreated SAWS has a high mortality rate. However, most hospitalized patients considered at risk do not develop SAWS; therefore, assessment should identify patients requiring enhanced observation without assuming that every alcohol-dependent patient will deteriorate. ^[27]A1a

Risk assessment should be completed at presentation and repeated during the period of anticipated withdrawal. The evidence base evaluates admission symptoms, signs, clinical factors, and prediction tools, but does not establish a universally reliable bedside rule that replaces clinical reassessment. ^{[27]A1a[50]B2a[93]B2c} A history of previous complicated withdrawal is particularly important when determining the need for supervised treatment, because prediction studies specifically examined seizures and delirium tremens as clinically consequential outcomes. ^[50]B2a[151]

Risk prediction and screening tools

PAWSS was developed because existing withdrawal-severity scales, including the Clinical Institute Withdrawal Assessment for Alcohol (CIWA), quantify current withdrawal severity but do not identify patients at risk before significant symptoms develop. The PAWSS systematic review and pilot study sought to identify clinical predictors, develop a prediction tool, and assess its validity in patients at risk; the authors emphasized that validated prediction tools for medically ill patients were previously lacking. ^[50]B2a A numeric PAWSS cutoff should therefore be used only in accordance with local validation and protocol governance; the supplied evidence does not establish a universal threshold for all clinical settings. ^[50]B2a

The admission AUDIT-PC was studied retrospectively among medical-surgical inpatients admitted outside intensive care to determine whether alcohol-use consumption screening predicted subsequent withdrawal. This supports structured admission screening, but the study was designed in a non-intensive-care population and should not be treated as proof that AUDIT-PC alone safely excludes severe withdrawal or determines treatment intensity. ^[8]B3b The Glasgow Assessment and Management guideline combined the Fast Alcohol Screening Test for identifying at-risk patients, risk stratification to select fixed-dose or symptom-triggered benzodiazepine treatment, and the Glasgow Modified Alcohol Withdrawal Scale for symptom-triggered treatment in general hospitals. ^[152]D

Machine-learning models have also been investigated using admission-accessible clinical, laboratory, and sociodemographic variables. In two detoxification wards, the analysis included 389 and 805 patients and used nested cross-validation with out-of-sample validation to predict moderate-to-severe withdrawal, delirium tremens, and withdrawal seizures. The models separated mild from more severe withdrawal with statistically significant, although incompletely characterized, performance in the supplied report; these methods remain adjuncts to clinical assessment rather than established replacements for bedside judgment. ^[93]B2c

Predictors of complicated withdrawal

Among 827 inpatients treated for moderate-to-severe withdrawal with score-guided, symptom-triggered therapy, delayed progression to peak withdrawal severity was associated with withdrawal seizures. Structural brain lesions in the medical history were also identified as a seizure predictor. These findings support continued observation when withdrawal severity is still evolving and a lower threshold for specialist review in patients with neurological vulnerability. ^[151]

The systematic review of hospitalized adults evaluated symptoms and signs for predicting SAWS, including delirium tremens, withdrawal seizures, and clinically diagnosed severe withdrawal. Its central clinical implication is that risk stratification should combine history, examination, and observed trajectory rather than rely on a single symptom or sign. ^[27]A1a

Capacity and therapeutic setting

Capacity assessment should be integrated into the initial safety evaluation, particularly when intoxication, withdrawal-related confusion, delirium, or severe autonomic symptoms may impair understanding, reasoning, or communication. The supplied references do not validate a specific capacity instrument or provide a withdrawal-specific legal capacity threshold; capacity should therefore be assessed clinically and reassessed when mental status changes. ^{[27]A1a[50]B2a}

Patients with suspected or evolving severe withdrawal should be managed in a setting capable of frequent reassessment, objective scoring, seizure precautions, escalation of monitoring, and rapid treatment. Evidence spans emergency-department care, general hospitals, non-intensive-care medical-surgical wards, and dedicated detoxification wards; the appropriate location depends on current severity, trajectory, comorbidity, staffing, and monitoring capability. ^{[8]B3b[93]B2c[152]D[153]D} Emergency-department guidance emphasizes routine identification of risk, monitoring progression with an alcohol-withdrawal scale, and objective, symptom-triggered treatment to prevent deterioration. ^[153]D

The supplied studies do not provide evidence that pregabalin is a validated risk-stratification method or that it defines the appropriate therapeutic setting; the cited article is a critical review of pregabalin for alcohol dependence rather than a study establishing safe withdrawal triage. ^[94]D5 Similarly, the microsurgical reconstruction study concerns postoperative outcomes in patients with alcohol-induced mental disorders and does not provide evidence for AWS risk prediction or withdrawal-site selection. ^[95]B3b Police-custody screening research demonstrates limitations of health screening in that setting but does not validate an AWS assessment pathway. ^[96]B2b

Early pharmacologic principles

Alcohol withdrawal syndrome (AWS) reflects neuroadaptation to chronic ethanol exposure, characterized by reduced inhibitory γ-aminobutyric acid activity and increased excitatory glutamatergic activity when alcohol is discontinued. ^[56]A1c These mechanisms established the rationale for replacing or augmenting deficient inhibitory signaling and suppressing excitatory activity during withdrawal. ^[56]A1c Benzodiazepines became the conventional pharmacologic treatment because they address withdrawal symptoms and are used to prevent severe complications, including seizures and delirium tremens. ^[70]B2b Contemporary hospital practice commonly uses symptom-triggered benzodiazepine treatment guided by the Clinical Institute Withdrawal Assessment for Alcohol—revised (CIWA-Ar), although fixed-dose regimens and alternative agents have increasingly been studied. ^[70]B2b

Guideline-based modern care

The American Society of Addiction Medicine (ASAM) issued its first guideline on alcohol-withdrawal delirium in 2004 and released a broader Clinical Practice Guideline on Alcohol Withdrawal Management in May 2020 for adults hospitalized with AWS of any severity. ^[65]A1c The guideline reflects a shift from treating delirium tremens alone toward structured assessment and management across the full spectrum of withdrawal severity. ^[65]A1c Emergency-department practice has also become more standardized: the 2024 SAEM GRACE-4 guideline used the GRADE framework to address adult emergency-department patients with AWS, alcohol use disorder, and related presentations. ^[44]A1c

Risk stratification has evolved alongside treatment selection. A retrospective trauma-center study of 1,011 adults evaluated combinations of admission variables for estimating AWS risk, while a machine-learning analysis of 1,194 patients from two detoxification wards used clinical, laboratory, and sociodemographic features to predict moderate-to-severe withdrawal, delirium tremens, and withdrawal seizures. ^{[31]B2b [93]B2c} These approaches reflect increasing emphasis on identifying patients who require closer monitoring or prophylactic treatment rather than waiting for symptoms to progress. ^{[31]B2b [93]B2c}

Phenobarbital and benzodiazepine-sparing strategies

Phenobarbital has re-emerged as an adjunct to benzodiazepines or as alternative monotherapy, supported by its long half-life and activity at γ-aminobutyric acid receptors. ^[101]D5 ASAM recommends phenobarbital in selected clinical contexts, but the 2025 clinical review emphasizes that the evidence base remains limited, although sufficient to demonstrate safety and efficacy as a benzodiazepine alternative. ^[101]D5 A retrospective comparison of front-loaded phenobarbital regimens found that a subsequent taper did not necessarily provide additional benefit compared with no taper, consistent with the expectation that phenobarbital’s long half-life permits an auto-tapering effect. ^[155]C

Other GABAergic or anticonvulsant approaches have been investigated as benzodiazepine-sparing treatments. In an inpatient randomized trial of 63 patients receiving benzodiazepine-assisted detoxification, baclofen at 30 mg/day or 60 mg/day for 7 days reduced the need for additional diazepam compared with placebo, but available evidence remained insufficient to establish baclofen-assisted withdrawal as standard care. ^[77]A1b A randomized open-label hospital trial enrolled 88 patients with PAWSS ≥4 and compared a fixed-dose gabapentin taper with CIWA-Ar-directed benzodiazepines, addressing the limited evidence for gabapentin in hospitalized patients. ^[70]B2b Separately, a 16-week randomized trial of 68 adults with AUD and a history of AWS found that gabapentin 1,200 mg/day was associated with neurobiological investigation of dorsal anterior cingulate cortex GABA and glutamate levels, reflecting expansion of treatment research beyond acute symptom suppression toward relapse-related mechanisms. ^[97]A1b

A placebo-controlled trial of vigabatrin, 2 g/day for 4 days, enrolled 120 patients in a residential withdrawal unit and assessed whether inhibition of GABA transaminase could reduce the need for diazepam. ^[78]A1b Magnesium has likewise been tested as an adjunct because hypomagnesemia may contribute to withdrawal severity; a multicenter, double-blind trial administered oral magnesium lactate providing 426.6 mg/day for up to 15 days to inpatients with baseline CIWA-Ar scores >8. ^[52]A1b

Adjunctive sedation and nonpharmacologic approaches

Dexmedetomidine, an α2-adrenergic sedative, has been explored as an alternative or adjunct to diazepam, particularly when autonomic hyperactivity and intensive monitoring are prominent. ^[154] In a randomized trial of 40 patients, dexmedetomidine infusion at 0.2–0.7 μg/kg/min was compared with intravenous diazepam at 5–20 mg; the dexmedetomidine group showed significant sedation findings in patients with grade I/II traumatic brain injury, while hemodynamic effects were directly evaluated. ^[154] A later retrospective cohort study compared dexmedetomidine-treated and non-dexmedetomidine-treated AWS patients for ICU stay, hospital length of stay, mortality, and readmission, illustrating continuing uncertainty about its effect on meaningful clinical outcomes. ^[69]B3b

Nonpharmacologic adjuncts have also been tested. In a double-blind randomized sham-controlled trial involving 117 men, transcutaneous electrical acupoint stimulation combined with diazepam was compared with diazepam plus sham stimulation for 14 days; withdrawal, anxiety-related, sleep, and daytime-somnolence measures improved in both groups. ^[60]A1b

Reconsideration of ethanol and special populations

Ethanol administration has periodically been proposed as a pharmacologic substitute because it acts on both γ-aminobutyric acid-A and N-methyl-D-aspartate receptors. ^[102]A1a A 2024 systematic review critically evaluated oral and intravenous ethanol for prevention or treatment of AWS, while a UK NHS retrospective implementation study used oral ethanol for patients considered at high risk of delirium tremens, typically consuming ≥30 units/day, or with prior severe withdrawal, seizures, or delirium tremens. ^{[102]A1a [147]C} These data represent renewed interest rather than replacement of benzodiazepines as routine therapy. ^[102]A1a

Treatment evolution has also highlighted comorbidity and downstream safety. In hospitalized alcohol-associated hepatitis, a multinational retrospective cohort examined AWS prevalence, predictors, management, and mortality, including the possible role of prophylaxis. ^[30]B2b Severe withdrawal among patients receiving inpatient AUD treatment was associated with investigation of suicidal acts during a 2-year follow-up, reinforcing the need to connect acute withdrawal management with ongoing addiction and psychiatric care. ^[103]B2b Overall, modern treatment has progressed from predominantly benzodiazepine-based symptom control toward risk-stratified, monitored, and individualized use of benzodiazepines, phenobarbital, selected adjuncts, and integrated AUD treatment, while evidence for many alternatives remains preliminary. ^{[44]A1c [65]A1c [101]D5}

Clinical burden and serious complications

Alcohol withdrawal syndrome (AWS) ranges from mild autonomic and neuropsychiatric symptoms to seizures, delirium tremens, severe agitation, critical illness, and death; its potential severity contributes substantially to morbidity and mortality in emergency, medical, surgical-trauma, and intensive-care populations. ^{[74]A1a[46]A1a[131][136]} In a primary-care-linked cohort, AWS was identified as an important and potentially preventable cause or complication of hospitalization, although the supplied evidence does not provide the overall incidence estimate. ^[128] Hospitalized patients with a Prediction of Alcohol Withdrawal Severity Scale (PAWSS) score of ≥4 were considered at risk for complicated withdrawal in a randomized trial of gabapentin versus benzodiazepines. ^[70]B2b

Seizures and delirium tremens are principal withdrawal-related complications that prophylactic pharmacotherapy seeks to prevent. ^[70]B2b In a surgical-trauma ICU cohort, AWS-related complications were defined as severe agitation, delirium tremens, or seizures occurring after phenobarbital initiation, highlighting the need to distinguish persistent withdrawal from treatment-related sedation or other critical illness. ^[131] Trauma patients are considered a particularly vulnerable group because AWS is associated with increased morbidity and mortality in this setting. ^[136]

Comorbidity and high-risk populations

Alcohol-associated liver disease (ALD) complicates AWS treatment because altered drug metabolism may increase medication toxicity. ^[156] In patients with alcohol-associated hepatitis, AWS prevalence, predictors, management, and mortality were examined in a multinational retrospective cohort; the study specifically evaluated mortality as the primary outcome and adjusted multivariable analyses for demographic variables and disease severity. ^[30]B2b The supplied abstract does not report the numerical prevalence, mortality estimate, or prophylaxis effect, so these outcomes should not be inferred.

A separate retrospective comparison of hospitalizations managed under a CIWA-Ar protocol found that patients with liver disease had a higher prevalence of alcohol use disorder (94.3% vs 58.0%) and a longer hospital length of stay than patients without liver disease; the reported median stays were 93 hours (IQR 51–173) versus 69 hours (IQR 43–125), respectively. ^[142] In ALD with severe AWS requiring ICU care, a MIMIC-IV retrospective cohort compared phenobarbital with benzodiazepines using inverse-probability-of-treatment weighting; the rationale included concerns about oversedation, hepatic encephalopathy, respiratory depression, and altered metabolism, but the supplied abstract does not provide the comparative outcome results. ^[156]

Pregnancy and early postpartum withdrawal represent high-consequence clinical contexts. In a Mayo Clinic retrospective series, only 8 pregnant patients were identified among records of patients treated under a CIWA-Ar protocol; median peak CIWA-Ar was 17 (IQR 14), and maternal, fetal, labor, and neonatal outcomes were reviewed. ^[140]C The available abstract indicates clinically important maternal complications but does not provide complete numerical outcome data; evidence remains limited by the very small sample and retrospective design. ^[140]C

Sex and age may influence the clinical phenotype and course. A cohort of 10,092 hospitalized patients aged ≥21 years included 30.2% women and evaluated AWS manifestations and hospital course across four age groups: 21–39, 40–64, 65–74, and ≥75 years. ^[36]B2b A separate tertiary alcohol-related-disease-unit cohort included 907 patients, of whom 238 (26.2%) were women, and compared psychiatric and medical manifestations, including AWS severity; the supplied results indicate similar prevalences of atrial fibrillation, ischemic cardiomyopathy, alcohol-related cognitive impairment, and AWS severity between sexes. ^[125]

Treatment-related harm and monitoring

Benzodiazepines remain standard first-line therapy, but clinically important concerns include oversedation, respiratory depression, delirium, and treatment-refractory withdrawal. ^{[46]A1a[66]A1a[136][156]} Phenobarbital is used as an alternative or adjunct when benzodiazepines are insufficient or unavailable, but systematic reviews emphasize uncertainty regarding optimal dosing and the limited quality and heterogeneity of direct evidence. ^{[74]A1a[46]A1a[66]A1a} Emergency-department evidence has evaluated AWS complications, monitored-setting admission, symptom control, adverse effects, and need for adjunctive medication, but the supplied abstract does not provide pooled numerical estimates. ^[74]A1a

Phenobarbital-based strategies have been studied in ED, ICU, and trauma populations, including phenobarbital monotherapy, adjunctive therapy, and low-dose oral regimens. ^{[46]A1a[66]A1a[131][136]} The trauma comparison specifically evaluated a low-dose oral phenobarbital protocol against a benzodiazepine regimen, while excluding patients taking benzodiazepines or barbiturates before admission and those who received propofol or dexmedetomidine before protocol initiation. ^[136] These exclusions limit direct generalization to patients with pre-existing sedative exposure or early need for rescue sedation. ^[136]

Gabapentin is an evidence-based outpatient alternative, but its role in hospitalized AWS is less established. ^[70]B2b An open-label randomized trial enrolled 88 adults with PAWSS ≥4 and compared a fixed-dose gabapentin taper with CIWA-directed benzodiazepines after randomization within 16 hours of admission. ^[70]B2b A systematic review and meta-analysis identified 8 retrospective studies involving 2,030 patients and examined symptom-resolution time, benzodiazepine exposure, symptom-resolution rates, serious withdrawal complications, and length of stay; it found no randomized studies in the included evidence base. ^[75]A1a Consequently, gabapentin should not be assumed to prevent severe complications as reliably as benzodiazepines in high-risk inpatients solely from the retrospective literature. ^[75]A1a

Dexmedetomidine may reduce apparent CIWA-Ar scores and sedative requirements, but it does not establish control of the underlying pathophysiology of withdrawal. ^[69]B3b A retrospective cohort compared dexmedetomidine-containing and non-dexmedetomidine treatment with ICU length of stay, hospital length of stay, mortality, and readmission as outcomes; the supplied abstract does not report the comparative results. ^[69]B3b Electronic order-set evaluation found inconsistent hospital AWS treatment and assessed guideline concordance in laboratory testing, severe-withdrawal risk assessment, symptom assessment, treatment, and associated management changes, indicating that protocol design itself may contribute to preventable variation and iatrogenic harm. ^[149]

Practical safety implications

Patients with suspected severe AWS, PAWSS ≥4, seizures, delirium, severe agitation, major liver disease, pregnancy, or clinically significant cardiopulmonary comorbidity require close reassessment and appropriately monitored care. ^{[70]B2b[131][140]C[142][156]} Sedative selection and dosing should account for hepatic dysfunction and the risks of respiratory depression, oversedation, hepatic encephalopathy, and masking of neurologic deterioration. ^[142][156] Evidence comparing phenobarbital, benzodiazepines, gabapentin, and dexmedetomidine remains substantially observational or heterogeneous; treatment decisions should therefore avoid interpreting reduced symptom scores alone as proof of reduced complications. ^{[46]A1a[66]A1a[69]B3b[75]A1a}

Overall course and severity

Alcohol withdrawal syndrome (AWS) has a variable clinical trajectory, ranging from mild, self-limited symptoms to seizures, delirium tremens (DT), intensive-care admission, mechanical ventilation, and death. ^[137] The majority of patients who develop withdrawal have mild symptoms, whereas a smaller proportion develops seizures or DT. ^[137] Withdrawal severity is clinically important because higher maximum withdrawal scores have been associated with longer hospital stays and increased in-hospital mortality. ^[58]B3b

The Clinical Institute Withdrawal Assessment for Alcohol—revised (CIWA-Ar) is widely used to follow symptom progression and treatment response, although its ability to quantify withdrawal is limited in patients who cannot reliably communicate or participate in scoring. ^[55]A1a A systematic review and meta-analysis found that aggregated CIWA-Ar scores generally track the clinical course of AWS and permit comparison of benzodiazepine (BZD) and non-BZD treatment approaches. ^[55]A1a

Predictors of severe or complicated withdrawal

Risk assessment at presentation can help identify patients likely to require admission or intensive monitoring. The Alcohol Withdrawal Triage Tool was derived and validated using objective information available during an emergency-department evaluation; its severe AWS composite included DT, withdrawal seizure, or high BZD requirements. ^[137] A separate machine-learning study used admission clinical, laboratory, and sociodemographic variables to distinguish mild from moderate-to-severe withdrawal and to predict DT and withdrawal seizures, with out-of-sample validation in two detoxification cohorts. ^[93]B2c These tools support risk stratification but do not replace repeated clinical assessment. ^[93]B2c[137]

Age, sex, and hospital course may differ across patient groups. In a cohort of 16,190 hospitalizations, women represented 30.2% of included hospitalizations; patients were categorized as 21–39, 40–64, 65–74, and ≥75 years. ^[36]B2b The study was specifically designed to evaluate age- and sex-related differences in AWS prevalence, manifestations, and hospital course, indicating that prognosis should not be inferred from a single demographic profile. ^[36]B2b

Patients with alcohol-associated hepatitis constitute a particularly vulnerable population. In a multinational retrospective cohort of patients hospitalized with alcohol-associated hepatitis, investigators evaluated AWS prevalence, predictors, management, mortality, and the potential role of prophylaxis while adjusting for demographic variables and disease severity. ^[30]B2b In a Japanese cohort of 88 patients with alcoholic hepatitis, outcomes were examined according to acute-on-chronic liver failure, DT, and related clinical features; the authors highlighted that loss of contact after DT may contribute to missed critical events. ^[40]C4

Treatment intensity and hospital outcomes

Early recognition and focused treatment may influence resource use in severe AWS. In a pre-post cohort of patients requiring >30 mg of diazepam, concentrating >50% of total diazepam administration within the first 24 hours was evaluated for its effect on hospital length of stay after evidence suggesting that early escalation may reduce ICU length of stay. ^[172]C In a national Veterans Health Administration cohort of 6,938 medical inpatients, initial BZD strategies were fixed-dose, symptom-triggered, or front-loaded in 41.9%, 40.8%, and 17.3% of patients, respectively; the study examined associations between strategy, cumulative BZD exposure, ICU care, and intubation. ^[5]B2c

In critically ill adults, phenobarbital-based and BZD-based pathways have been compared in a systematic review and meta-analysis of comparative studies, with analyses addressing pathway design and the timing of phenobarbital use. ^[169] Real-world ICU phenobarbital use has also been studied as a marker of severe or refractory withdrawal and treatment escalation, with propensity matching used to examine time to discharge and safety outcomes against nonphenobarbital regimens. ^[171] Other retrospective studies evaluated phenobarbital combined with BZDs versus BZD monotherapy for time to AWS resolution and safety outcomes, ^[126] and compared phenobarbital/lorazepam with dexmedetomidine/lorazepam for hospital and ICU length of stay, mechanical ventilation incidence, and ventilation duration. ^[114]B3b Because these observational studies are vulnerable to confounding by indication—sicker patients are more likely to receive escalation therapy—associations with outcome should not be interpreted as proof of treatment causation. ^{[114]B3b[126][171]}

A randomized ICU study found that adding dexmedetomidine to symptom-triggered BZD therapy was evaluated for arousable sedation and adrenergic control without respiratory depression; patients were titrated toward a Richmond Agitation-Sedation Scale of −2 to 0. ^[170] A network meta-analysis of 41 studies involving 4,187 participants found no significant difference in CIWA-Ar reduction between BZDs and other medication classes or combinations; anticonvulsant plus BZD therapy was associated with a shorter ICU stay by 1.71 days (95% CI, −2.82 to −0.59) compared with BZDs. ^[57]A1a

Non-BZD and adjunctive therapies

Evidence for alternatives and adjuncts remains heterogeneous and generally concerns symptom control or BZD exposure rather than long-term recovery. ^[57]A1a In uncomplicated AWS, a randomized study compared a 9-day decremental fixed-dose regimen of baclofen 30 mg with chlordiazepoxide 75 mg, assessing CIWA-Ar efficacy and tolerability. ^[107]A1b A randomized placebo-controlled trial of intranasal oxytocin enrolled 40 patients undergoing three-day detoxification with symptom-triggered oxazepam guided by CIWA-Ar. ^[81]A1b A placebo-controlled trial of vigabatrin enrolled 120 patients in a residential withdrawal unit and assessed the need for diazepam and total diazepam dose over acute withdrawal treatment. ^[78]A1b Transcutaneous electrical acupoint stimulation combined with diazepam was compared with sham stimulation plus diazepam in 117 men treated for 14 days; CIWA-Ar, anxiety or symptom burden, sleep quality, and sleepiness outcomes improved in both groups. ^[60]A1b

A standardized protocol for psychiatric inpatients was evaluated retrospectively before and after implementation in 138 patients at risk for AWS, with outcomes compared with treatment as usual. ^[135] These studies suggest that structured monitoring and protocolized treatment may affect short-term symptom and utilization outcomes, but the available evidence does not establish that any adjunct changes the underlying risk of recurrent alcohol use, repeated withdrawal, or long-term mortality. ^{[57]A1a[78]A1b[81]A1b[107]A1b[135]}

Prognostic interpretation

Maximum withdrawal severity, early benzodiazepine requirements, DT, seizures, ICU transfer, and respiratory support are clinically meaningful markers of a complicated course. ^{[5]B2c[58]B3b[137][172]C} Prognosis should therefore be reassessed dynamically rather than based solely on the initial presentation or a single CIWA-Ar value. ^{[55]A1a[93]B2c[137]} Across pharmacologic studies, apparent differences in ICU or hospital outcomes must be interpreted in the context of illness severity, treatment timing, pathway design, and selection for rescue therapy. ^{[57]A1a[114]B3b[126][169][171]}

Scope and evidence limitations

Pregnancy-associated alcohol withdrawal syndrome (AWS) is substantially under-researched. In the available pregnancy-specific study, only 8 pregnant patients were identified among Mayo Clinic admissions managed using a CIWA-Ar protocol from June 2019 through June 2022; the median peak CIWA-Ar score was 17 (interquartile range, 14), indicating clinically significant withdrawal in this small series.^[140]C The study evaluated pregnancy, labor, and neonatal records, but the evidence base remains too limited to establish pregnancy-specific comparative efficacy or safety for benzodiazepines, phenobarbital, anti-seizure medications (ASMs), or adjunctive agents.^[140]C The principal systematic review of ASMs included 24 randomized trials and 2223 adults, but it was restricted to participants older than 18 years and does not provide pregnancy-specific conclusions.^[110]A1a

Perinatal psychiatric assessment should therefore address both immediate withdrawal risk and alcohol-use-disorder treatment needs, while recognizing that evidence for fetal, neonatal, and postpartum psychiatric outcomes is sparse in the cited literature.^[140]C Severe withdrawal may produce rapidly changing maternal and fetal risk; the small pregnancy cohort’s high symptom scores support a low threshold for obstetric, addiction-medicine, anesthesia, and neonatal consultation.^[140]C

Assessment in pregnancy and other special populations

CIWA-Ar-based protocols can support structured monitoring, but scores should not be interpreted in isolation. CIWA-Ar may overestimate AWS when symptoms overlap with postoperative inflammation, systemic inflammatory response, pain, or other acute illness; a prospective postoperative study specifically examined the potential for false-positive scoring.^[163] In pregnant patients, tachycardia, nausea, anxiety, insomnia, and autonomic symptoms may likewise have obstetric or medical explanations, so diagnosis should integrate history, serial examination, vital signs, laboratory testing, and alternative-cause assessment.^[140]C[163]

Seizures or altered mental status require evaluation beyond presumed withdrawal. Among patients with alcohol-associated bacterial meningitis, 18% presented with seizures and 23% with co-existing pneumonia, demonstrating that seizure or delirium in a person with alcohol use should not automatically be attributed to AWS.^[48]B2b Trauma may further confound presentation: a case-control study evaluated alcohol exposure and AWS among 3896 hospitalized adult trauma patients, underscoring the need to distinguish intoxication, withdrawal, injury, and medical complications.^[2]B3b

Older adults may have additional vulnerability. A multicentre Spanish observational study examined alcohol use, AUD, and in-hospital complications among patients aged ≥80 years admitted to internal medicine; these patients should be assessed for frailty, polypharmacy, cognitive impairment, and complications when withdrawal is suspected.^[160]

Pharmacological management

Benzodiazepines remain the conventional inpatient treatment framework in the cited literature, including symptom-triggered lorazepam regimens for AWS and symptom-triggered diazepam protocols in emergency short-stay care.^[159]C[164]C In pregnancy, medication selection should be individualized according to withdrawal severity and the competing risks of untreated maternal withdrawal, maternal oversedation, and neonatal drug exposure; the cited pregnancy study does not establish a preferred agent or regimen.^[140]C

Evidence for ASMs is heterogeneous. The systematic review assessed efficacy outcomes including AWS-related seizures, delirium, and CIWA-Ar scores, but its adult-only evidence base does not justify assuming equivalent efficacy or safety during pregnancy.^[110]A1a Phenobarbital has been studied in adults as monotherapy, adjunctive treatment, and with or without a taper, but the available evidence is predominantly retrospective and non-pregnancy-specific.^{[113]B3b[114]B3b[155]C[162][164]C} Emergency-department data compared intravenous phenobarbital monotherapy with benzodiazepines or combination therapy,^[113]B3b while ICU and inpatient studies examined phenobarbital added to lorazepam or compared with benzodiazepines and dexmedetomidine.^{[114]B3b[161][162][164]C} These studies should not be extrapolated to fetal or neonatal safety.

In critically ill patients with primary neurologic injuries, phenobarbital was specifically evaluated against symptom-triggered benzodiazepines with oversedation as a safety outcome.^[161] In severe AWS, phenobarbital strategies have also been evaluated using hospital or ICU length of stay, mechanical ventilation, and benzodiazepine exposure as outcomes.^{[114]B3b[162][164]C} A phenobarbital taper study compared tapered with non-tapered regimens,^[155]C and a hospitalized cohort compared phenobarbital with dexmedetomidine as adjuncts to lorazepam.^[114]B3b These findings may inform specialist care for refractory adult AWS but do not provide pregnancy-specific recommendations.

Supportive care and systems of care

Thiamine replacement is commonly used in AWS cohorts, with 77% of one retrospective sample receiving thiamine.^[157] AUD patients admitted to intensive care may also have vitamin C deficiency; one observational study measured admission levels and levels after empiric supplementation.^[158]C Magnesium deserves attention because low serum magnesium was evaluated in relation to 1-year mortality in a cohort of 380 analyzable AWS patients, of whom 17% had died at one year.^[157] These studies establish clinical associations and practice patterns, not proof that supplementation changes maternal, fetal, neonatal, or psychiatric outcomes.^[157][158]C

Hospital protocols may improve recognition and standardization. Universal screening with PAWSS followed by GMAWS-guided treatment was evaluated for effects on length of stay, benzodiazepine dose, and AWS-attributable adverse events.^[143] National hospital practice patterns have also been examined in a multicentre cohort of 245271 adult inpatients,^[111]B3b and United States emergency-department presentations were assessed across 2016–2023.^[127] Hospitalization incidence in a primary-care population was studied from 2018–2022.^[128] These datasets support systematic detection but do not resolve pregnancy-specific management.

Perinatal psychiatric follow-up

After stabilization, care should include assessment and treatment of AUD, relapse risk, depression, anxiety, trauma, suicidality, social adversity, and parenting or safeguarding concerns; however, the cited studies do not quantify these perinatal psychiatric outcomes.^[140]C Patients should receive coordinated postpartum follow-up because early postpartum presentation was included in the pregnancy-focused investigation, while evidence for recurrence, neonatal neurobehavioral effects, and engagement with ongoing psychiatric treatment remains insufficient.^[140]C

High-risk clinical contexts

Delirium tremens may be missed after apparent clinical improvement; a Japanese alcoholic-hepatitis study specifically examined loss of contact after delirium tremens and the possibility of missed critical events.^[40]C4 AWS in trauma, neurologic injury, severe medical illness, or pregnancy should therefore be managed with continuous reassessment and a search for competing diagnoses rather than reliance on a single withdrawal score.^{[2]B3b[40]C4[48]B2b[161][163]}

Prevention objectives and population identification

Alcohol withdrawal syndrome (AWS) is potentially life-threatening but preventable or modifiable when patients at risk are identified before symptoms become severe. Hospitalized patients with alcohol dependence, trauma, critical illness, liver disease, or a prior history of complicated withdrawal require particular attention. ^{[115]A1a [118]D5 [167]D} Alcohol-related hospitalizations are common in primary care populations, and AWS may develop during admission rather than being present at presentation. ^[128] Older adults may be especially vulnerable because alcohol use, alcohol use disorder, comorbidity, and medication exposure can coexist in this group. ^[160]

Universal alcohol-use screening at admission is therefore appropriate where feasible, followed by structured assessment of withdrawal risk. A recent hospital protocol screened all non-critical-care admissions for alcohol use and then used the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) to identify patients requiring further assessment. ^[143] Screening should distinguish alcohol exposure or AUD from current withdrawal: the AUDIT and AUDIT-PC support alcohol-use assessment, whereas CIWA-Ar and related symptom scales quantify current withdrawal severity and do not reliably predict who will subsequently develop AWS. ^{[8]B3b [50]B2a} In hospitalized medical-surgical patients, admission AUDIT-PC scores were evaluated specifically for prediction of AWS developing later during the admission. ^[8]B3b

Risk stratification before symptoms escalate

Risk assessment should include prior withdrawal seizures or delirium tremens, previous severe AWS, recent reduction or cessation of heavy alcohol use, autonomic or neuropsychiatric symptoms, concurrent sedative or stimulant exposure, significant medical illness, abnormal laboratory findings, and inability to participate reliably in monitoring. ^{[35]B3b [50]B2a} In trauma populations, multifactorial strategies incorporating drinking history, blood alcohol concentration, demographic factors, and clinical variables were developed to estimate the probability of AWS. ^[31]B2b In acute hospital cohorts, multiple clinical variables were associated with severe AWS, although the literature has not established a universally accepted risk-factor set. ^[35]B3b

PAWSS was developed to address the limitation that symptom-severity instruments identify established withdrawal but not patients who may benefit from timely prophylaxis. ^[50]B2a Machine-learning models using admission clinical, laboratory, and sociodemographic data have also shown the ability to separate mild from more severe withdrawal and to predict delirium tremens and withdrawal seizures in detoxification-ward populations; these models remain adjunctive tools rather than replacements for clinical assessment. ^[93]B2c In intensive care, screening is more difficult because delirium, mechanical ventilation, pain, anxiety, and sedation can obscure or mimic AWS; ICU-specific assessment and repeated reassessment are required. ^[115]A1a

Monitoring and early intervention

Patients at risk should receive a documented monitoring plan, repeated symptom assessment, vital-sign surveillance, medication review, nutritional assessment, and evaluation for electrolyte abnormalities, liver disease, infection, trauma, and alternative causes of delirium or autonomic instability. ^{[115]A1a [118]D5} Standardized electronic order sets can improve consistency, but published hospital order sets vary substantially and do not uniformly contain guideline-concordant laboratory testing, severe-withdrawal risk assessment, symptom assessment, or treatment instructions. ^[149]

A protocolized approach may reduce avoidable delays and treatment variation. In a retrospective six-year cohort, universal screening with PAWSS, subsequent Glasgow Modified Alcohol Withdrawal Scale assessment, and treatment according to a predefined protocol were evaluated for effects on length of stay, benzodiazepine exposure, and AWS-attributable adverse events. ^[143] Economic evidence remains limited: a 2025 systematic review found only 8 eligible studies among 6,347 identified records, indicating that cost-effectiveness conclusions for AWS interventions remain uncertain. ^[72]B2a

Pharmacological prophylaxis and outpatient detoxification

Patients with a high risk of complicated withdrawal should generally be managed in a setting capable of frequent observation and rapid treatment; benzodiazepines remain central to monitored withdrawal care, particularly in severe AWS, delirium tremens, or seizure risk. ^{[115]A1a [118]D5 [167]D} In alcohol-associated liver disease, treatment should account for hepatic dysfunction and the need to address the underlying AUD; monitored care and standardized symptom-triggered benzodiazepine protocols are commonly appropriate according to clinical severity. ^[167]D

Evidence for routine pharmacological prevention before symptoms develop is limited. A trauma-center evaluation compared phenobarbital prophylaxis with symptom-triggered management in risk-matched patients, reflecting the substantial concern for AWS in trauma admissions, but the available evidence was observational and the study itself described prevention data as limited. ^[168]D Phenobarbital should therefore not be treated as universally indicated; respiratory depression, sedation, interactions, hepatic disease, and the need for experienced monitoring must be considered. ^{[115]A1a [168]D}

Low-risk patients who meet strict medical, psychiatric, social, and monitoring criteria may be considered for outpatient detoxification. Small open-label outpatient studies reported successful completion with levetiracetam, either alone with diazepam rescue or combined with tiapride, over a maximum of 7 days, but these findings are observational or case-series evidence and do not establish equivalence to benzodiazepine-based care. ^{[117]C4 [165]} In uncomplicated inpatient withdrawal, a randomized double-blind comparison evaluated fixed-dose lorazepam and chlordiazepoxide schedules tapered to zero over 8 treatment days; both agents are established options, with selection influenced by hepatic function, age, comorbidity, duration of action, and monitoring capacity. ^[116]A1b Baclofen has been assessed in Cochrane reviews, but the evidence base was based on trials available through 2010 and 2012, so it should not replace standard monitored treatment for severe or complicated AWS without specialist oversight. ^{[14]A1a [13]A1a} A small 2026 ambulatory case series also evaluated a 6-day fixed-dose gabapentin taper in carefully selected low-risk patients with follow-up through one month; its sample size and evidence level preclude broad generalization. ^[166]C

Safety threshold for escalation

Any patient with seizures, delirium, severe agitation, hallucinations, marked autonomic instability, worsening mental status, significant comorbidity, or inadequate outpatient support requires urgent escalation to a higher-acuity setting. ^{[115]A1a [118]D5} Prevention is not synonymous with suppressing symptoms: early recognition must occur alongside evaluation for Wernicke encephalopathy, metabolic disturbance, infection, trauma, hepatic encephalopathy, and other causes of delirium. ^{[118]D5 [167]D}